{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:15:54Z","timestamp":1779358554127,"version":"3.51.4"},"reference-count":22,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T00:00:00Z","timestamp":1526860800000},"content-version":"vor","delay-in-days":166,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>The Action to Control Cardiovascular Risk in Diabetes Blood Pressure (ACCORD-BP) study did not find a significant beneficial effect of intensive systolic blood pressure (SBP) lowering on cardiovascular events in hypertensive patients with type 2 diabetes mellitus (T2DM), while the Systolic Blood Pressure Intervention Trial (SPRINT) did find a significant beneficial effect in patients without T2DM. The objective of this analysis was to assess the effect of both T2DM and baseline cardiovascular disease risk on the treatment effect of intensive blood pressure lowering.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>The individual patient data from the ACCORD-BP and SPRINT studies were pooled and follow-up durations harmonized. Both studies randomized hypertensive patients to an SBP target of &amp;lt;120 mmHg or a target of &amp;lt;140 mmHg. The composite primary end point consisted of unstable angina, myocardial infarction, acute heart failure, stroke, and cardiovascular death. The interaction between intensive blood pressure lowering and both T2DM and 10-year cardiovascular risk was assessed using Cox proportional hazards models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>The cohort consisted of 14,094 patients with mean age 66 \u00b1 8.9 years and mean baseline SBP 139.5 \u00b1 15.6 mmHg; 33.6% had T2DM. The hazard ratio for the primary composite end point was 0.82 (95% CI 0.73\u20130.93), P = 0.0017. The interaction between intensive blood pressure lowering and T2DM was nonsignificant (P = 0.13). The 10-year cardiovascular risk was higher in primary prevention patients with T2DM, but risk did not interact with the treatment effect (P = 0.84).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Intensive blood pressure lowering may have a similar favorable effect and appears to decrease cardiovascular events in both patients with and patients without T2DM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc17-1722","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T01:25:43Z","timestamp":1512609943000},"page":"1142-1148","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":39,"title":["Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials"],"prefix":"10.2337","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8379-7470","authenticated-orcid":false,"given":"Tom F.","family":"Brouwer","sequence":"first","affiliation":[{"name":"Heart Center, Department of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim T.","family":"Vehmeijer","sequence":"additional","affiliation":[{"name":"Heart Center, Department of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah N.","family":"Kalkman","sequence":"additional","affiliation":[{"name":"Heart Center, Department of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter R.","family":"Berger","sequence":"additional","affiliation":[{"name":"Heart Center, Department of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bert-Jan H.","family":"van den Born","sequence":"additional","affiliation":[{"name":"Department of Internal and Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron J.","family":"Peters","sequence":"additional","affiliation":[{"name":"Heart Center, Department of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinoud E.","family":"Knops","sequence":"additional","affiliation":[{"name":"Heart Center, Department of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2017,12,6]]},"reference":[{"key":"2022031301165896300_B1","first-page":"2","volume":"13","year":"1989","journal-title":"Hypertension"},{"key":"2022031301165896300_B2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/bmj.38678.389583.7C","article-title":"Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies","volume":"332","author":"Huxley","year":"2006","journal-title":"BMJ"},{"key":"2022031301165896300_B3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"2022031301165896300_B4","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"2022031301165896300_B5","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031301165896300_B6","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1161\/HYP.0000000000000018","article-title":"Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension","volume":"65","author":"Rosendorff","year":"2015","journal-title":"Hypertension"},{"key":"2022031301165896300_B7","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"2022031301165896300_B8"},{"key":"2022031301165896300_B9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"2022031301165896300_B10","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/1740774514537404","article-title":"The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)","volume":"11","author":"Ambrosius","year":"2014","journal-title":"Clin Trials"},{"key":"2022031301165896300_B11","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.amjcard.2007.03.005","article-title":"Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"99","author":"Cushman","year":"2007","journal-title":"Am J Cardiol"},{"key":"2022031301165896300_B12","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"2022031301165896300_B13"},{"key":"2022031301165896300_B14","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMe1513301","article-title":"Redefining blood-pressure targets--SPRINT starts the marathon","volume":"373","author":"Perkovic","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031301165896300_B15"},{"key":"2022031301165896300_B16","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/HJH.0000000000001276","article-title":"Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials","volume":"35","author":"Thomopoulos","year":"2017","journal-title":"J Hypertens"},{"key":"2022031301165896300_B17","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031301165896300_B18","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031301165896300_B19"},{"key":"2022031301165896300_B20","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/HYPERTENSIONAHA.116.07257","article-title":"Unattended blood pressure measurements in the systolic blood pressure intervention trial: implications for entry and achieved blood pressure values compared with other trials","volume":"67","author":"Kjeldsen","year":"2016","journal-title":"Hypertension"},{"key":"2022031301165896300_B21","doi-asserted-by":"crossref","first-page":"d286","DOI":"10.1136\/bmj.d286","article-title":"Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial","volume":"342","author":"Myers","year":"2011","journal-title":"BMJ"},{"key":"2022031301165896300_B22","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2337\/dci17-0026","article-title":"Diabetes and hypertension: a position statement by the American Diabetes Association","volume":"40","author":"de Boer","year":"2017","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/41\/6\/1142\/553583\/dc171722.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/41\/6\/1142\/553583\/dc171722.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T05:00:25Z","timestamp":1647147625000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/41\/6\/1142\/36480\/Intensive-Blood-Pressure-Lowering-in-Patients-With"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,6]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,12,6]]},"published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc17-1722","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,6]]}}}